What Remix Therapeutics does

Remix Therapeutics is a clinical-stage biotechnology company founded in 2020 and headquartered in Watertown, Massachusetts, that develops small molecule therapeutics designed to modulate RNA processing and thereby control the expression of disease-driving genes and proteins. Its scientific platform, REMaster, integrates machine learning algorithms with a proprietary transcriptome database (reported to cover more than 1.6 million novel exon targets, ~25x the largest public database), multiplexed high-throughput cell-based and cell-free screening, and a purpose-built RNA-targeted chemical library. The platform's lead clinical output is REM-422, a first-in-class, orally bioavailable small molecule mRNA degrader that induces poison exon inclusion in MYB mRNA, triggering nonsense-mediated decay and reducing MYB protein levels — a mechanism directed at a transcription factor historically considered undruggable.

REM-422 is currently in a Phase 1/2 study (ARIA) for recurrent/metastatic adenoid cystic carcinoma (ACC) and a Phase 1 study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome, conducted across eight US academic cancer centers. Interim data disclosed in 2026 reported a 43% overall response rate and 100% disease control rate at the recommended Phase 2 dose in ACC. The candidate has received FDA Orphan Drug Designation in ACC and AML and FDA Fast Track Designation in recurrent/metastatic ACC. Remix's pipeline also targets additional oncology indications and neurodegenerative diseases.

Remix is pre-revenue and generates cash through strategic R&D collaborations and equity financing rather than product sales. It received $45M upfront from Janssen (Johnson & Johnson) in 2022 and $30M upfront from Roche in 2024, each with potential milestone payments exceeding $1 billion plus tiered royalties, plus equity rounds totaling roughly $211M (including a $60M round in January 2024 led by The Column Group) and a $100M PIPE in June 2026 led by Decheng Capital concurrent with its announced reverse merger with Passage Bio (Nasdaq listing as RMTX expected Q4 2026, with pre-merger Remix holders owning ~93%).

Name

Remix Therapeutics

Legal name

Remix Therapeutics, Inc.

Website

https://remixtx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Remix Therapeutics is a clinical-stage Watertown, MA biotech developing small molecule drugs that modulate RNA processing via its REMaster platform, with lead candidate REM-422 (an oral MYB mRNA degrader) in Phase 1/2 trials for adenoid cystic carcinoma and AML.

Ownership category

akta.pro rank

Product category

RNA-Targeted Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• RNA processing therapeutics
• Small molecule discovery
• MRNA degrader technology
• Oncology drug development
• Clinical stage biotechnology

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical R&D/Partnership Revenues: Pre-revenue clinical-stage biotech company. Generates income through strategic partnerships with pharmaceutical companies including upfront payments, milestone payments, and royalty payments on potential commercial products. Received $45M upfront from Janssen collaboration (2022) and $30M upfront from Roche collaboration (2024).
2. Future Product Sales: Potential future revenue from commercialization of lead candidate REM-422 and other pipeline programs in oncology and neurodegeneration. REM-422 is currently in Phase 1/2 clinical trials for ACC and AML.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Remix Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics designed to modulate RNA processing and control gene expression. Its proprietary REMaster™ drug discovery platform uses machine learning, proprietary transcriptomic data, and high-throughput multiplexed screening to identify chemical matter against historically undruggable targets, with lead candidate REM-422, a first-in-class oral mRNA degrader targeting MYB, currently in Phase 1/2 clinical trials for adenoid cystic carcinoma and acute myeloid leukemia.

Product overview

Remix Therapeutics is advancing a new class of small molecule therapeutics designed to reprogram RNA processing. The company's core offering consists of the proprietary REMaster™ Drug Discovery Platform, which leverages machine learning, transcriptomic data, and high-throughput screening to identify compounds that modulate gene expression at the RNA level. The lead clinical candidate is REM-422, a first-in-class oral mRNA degrader targeting the MYB transcription factor, currently in Phase 1/2 trials for adenoid cystic carcinoma and Phase 1 for acute myeloid leukemia. The platform and pipeline address previously undruggable disease drivers in oncology and neurodegeneration.

Differentiator

Problem solved

Functional benefit

Products and services

• REMaster™ Drug Discovery Platform Proprietary drug discovery platform that identifies druggable RNA processing target sites and active chemical matter using machine learning algorithms, extensive transcriptomic datasets, multiplexed high-throughput cell-based and cell-free screening assays, and a proprietary RNA-targeted small molecule library, enabling modulation of gene expression for historically undruggable disease drivers.
• REM-422 First-in-class orally available small molecule mRNA degrader that targets the MYB transcription factor by inducing poison exon incorporation in MYB mRNA, leading to nonsense-mediated decay of the transcript and reduction of MYB protein expression. Currently in Phase 1/2 clinical trials for adenoid cystic carcinoma (ACC) and Phase 1 for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS); has received FDA Orphan Drug Designation for ACC and AML and FDA Fast Track designation for recurrent, metastatic or unresectable ACC.

Quantifiable outcome

• 43% overall response rate and 100% disease control rate in recurrent/metastatic ACC patients at recommended Phase 2 dose
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Passage BioflagshipStrategic or Co-development Partner · 24 June 2026All-stock reverse merger agreement. Pre-merger Remix stockholders will own approximately 93% of combined company. Combined entity will operate as Remix Therapeutics and trade on Nasdaq under ticker RMTX. Expected to close Q4 2026.
• RochecoreStrategic or Co-development Partner · 3 January 2024Collaboration and license agreement for discovery and development of small molecule therapeutics modulating RNA processing using Remix's REMaster platform. Remix received $30M upfront and up to $12M in near-term milestones, with potential total payments up to $1 billion plus tiered royalties. Roche receives exclusive rights to specific targets and is responsible for development and commercialization.
• Janssen Pharmaceutica NV (Johnson & Johnson)flagshipStrategic or Co-development Partner · 17 February 2022Multi-year, three target strategic collaboration for discovery and development of small molecule therapeutics modulating RNA processing in oncology and immunology. Remix received $45M upfront and may receive total payments potentially exceeding $1 billion including preclinical, clinical, commercial, sales milestones and tiered royalties. Remix has option to opt into one program's clinical development costs for higher royalties.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• ProQR Therapeutics: ProQR Therapeutics develops RNA-targeted therapeutics, including Axiomer RNA editing technology. It is a broad peer in the RNA therapeutics space with a different delivery modality but comparable focus on modulating RNA to treat genetic disease.
• Arvinas: Arvinas is a clinical-stage leader in targeted protein degradation (PROTAC). While it degrades proteins rather than mRNA, it pioneered the small molecule degrader modality and serves as the closest analog for Remix's mRNA degrader approach at scale.
• Syros Pharmaceuticals: Syros Pharmaceuticals pioneered small molecule gene expression control therapeutics. It is a broad peer to Remix in the gene regulation / transcription control space, with a longer operating history in clinical development.

Emerging players

• Stoke Therapeutics: Stoke Therapeutics develops antisense oligonucleotide medicines that increase protein production by modulating RNA splicing. It is an emerging peer in the RNA-targeted therapeutics space, with a different modality (ASO) than Remix's small molecules.

Direct peers

• Accent Therapeutics: Accent Therapeutics develops small molecule therapies that target RNA-modifying proteins, with a focus on oncology. It is comparable to Remix in the precision oncology / RNA biology space, though the molecular target class differs.
• Kymera Therapeutics: Kymera Therapeutics is a clinical-stage biotech developing small molecule targeted protein degraders using its Pegasus platform. It is comparable to Remix as a degrader-focused small molecule company pursuing historically undruggable oncology targets.
• Foghorn Therapeutics: Foghorn Therapeutics develops small molecule drugs that target chromatin regulatory systems to modulate gene expression. It is directly comparable to Remix as a clinical-stage precision oncology company that targets gene expression regulation.
• Expansion Therapeutics: Expansion Therapeutics develops small molecule RNA-targeting drugs, with a focus on repeat expansion diseases. It is a direct platform peer, leveraging small molecules to modulate RNA processing for therapeutic benefit.
• Arrakis Therapeutics: Arrakis Therapeutics designs small molecule drugs that bind RNA structures, including mRNA. It pursues a directly comparable approach to Remix, with platform-based RNA targeting and oncology/pipeline focus, supported by partnerships with large pharma.
• Skyhawk Therapeutics: Skyhawk Therapeutics develops small molecules that target RNA, including RNA splicing modulators. It is the closest direct competitor to Remix in the RNA-targeted small molecule space, with a similar platform-plus-pipeline model and major pharma partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/remixthera
• LinkedInlinkedin.com/company/remix-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remix Therapeutics